Labcorp
Labcorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.
Labcorp COVID-19 Antibody Testing Available Nationwide Learn more >>>
This test includes serial monitoring.
|
This test includes serial monitoring. |
11 - 25 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
For more information, please view the literature below.
Inflammatory Bowel Disease Biologics Flyer
Therapeutic Drug Monitoring Options for Rheumatoid Arthritis Brochure
Serum (preferred) or plasma
3 mL
1 mL (Note: This volume does not allow for repeat testing.)
Red-top tube, gel-barrier tube, plasma EDTA tube, or plasma heparin tube
Allow a minimum clotting time of 30 to 60 minutes with serum separation within 2 hours of collection. Send serum in a plastic transport tube. To avoid delays in turnaround time when requesting multiple tests on frozen samples, please submit separate frozen specimens for each test requested.
Frozen (preferred) or refrigerated
Temperature | Period |
---|---|
Room temperature | 14 days |
Refrigerated | 14 days |
Frozen | 14 days |
Freeze/thaw cycles | Stable x6 |
Provides ustekinumab drug concentration and anti‐ustekinumab antibodies in order to optimize treatment and facilitate clinical decision‐making.
This assay may be helpful in any patients on ustekinumab therapy for Crohn's disease, psoriasis, or other autoimmune conditions.
Drug concentration should be interpreted with confirmation of specimen collection timing.
Non‐trough concentrations may be misleading.
Trough blood collection (just before or within 24 hrs. of next dose) is suitable because target ranges and therapeutic cut‐offs have been established in clinical studies using trough concentration.
The drug half‐life should be taken into consideration when interpreting results from non‐perfect trough collections.
Some primary non‐responders have inadequate clinical response despite adequate trough levels.
As with other biologics, the optimal ustekinumab concentration depends upon patient‐specific factors including co‐morbidities, disease and desired therapeutic endpoint.
Positive anti‐ustekinumab antibodies should be interpreted in the context of the concomitant free ustekinumab drug level.
Electrochemiluminescence immunoassay (ECLIA)
Ustekinumab drug level: <0.1 μg/mL
• Result ≥0.1 μg/mL indicates detection of ustekinumab
• In the presence of anti-ustekinumab antibodies, the ustekinumab drug level reflects the free, antibody-unbound fraction of ustekinumab in serum.
Anti-ustekinumab antibody: <40 ng/mL
• Result ≥40ng/mL indicates detection of anti-ustekinumab antibodies.
Drug Assay: The ustekinumab drug level typically reflects the antibody-unbound (the free fraction) of ustekinumab when serum anti-ustekinumab antibodies are present. In the absence of anti-ustekinumab antibodies, the ustekinumab drug level typically reflects the total ustekinumab concentration in serum.
Anti-drug Antibody Assay: This anti-ustekinumab antibody assay is “drug-tolerant”, that is, the presence of serum ustekinumab does not impede the detection and quantitation of anti-ustekinumab antibodies. This anti-ustekinumab antibody assay is specific; antibodies against other biologic drugs do not cross-react with this assay. All positive anti-ustekinumab antibody results are verified by a confirmatory test.
Both drug and anti-drug antibody assays have been developed and validated in accordance with FDA Guidance for Industry documents: Bioanalytical Method Validation (2013) and Assay Development and Validation for Immunogenicity Testing of Therapeutic Protein Products (2016).
Order Code | Order Code Name | Order Loinc | Result Code | Result Code Name | UofM | Result LOINC |
---|---|---|---|---|---|---|
504594 | Ustekinumab and Anti-Ustek Ab | 504595 | Ustekinumab | ug/mL | 87408-1 | |
504594 | Ustekinumab and Anti-Ustek Ab | 504596 | Anti-Ustekinumab Antibody | ng/mL | 88992-3 |
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
CPT Statement/Profile Statement
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf